Sales & Marketing News | pharmaphorum

News

UK must not overlook manufacturing in life sciences drive

To meet its aspiration of becoming a life sciences superpower, the UK must not only discover and develop new medicines – it must also be able to manufacture them at scale,

News

Astellas hit by US patent verdict for incontinence drug

A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence is invalid, in a setback to its efforts to defend the blockb

News

Illumina CEO resigns amid investor pressure

Illumina chief executive Francis deSouza confirmed in a LinkedIn post today that he has handed in h

News

CMS extends list of drugs with penalties for price hikes

In a new update, the US government has more than doubled the size of the latest list of medicines subject to enforced rebates if their prices rise higher than inflation.

News

FDA panel gives unanimous support to Leqembi

The first full regulatory approval for an amyloid-targeting therapy for Alzheimer’s disease could come within a month, after an expert panel voted 6 to 0 in favour of Eisa

News

Teva gets its US opioid settlement over the finish line

After years of legal horse-trading, Teva looks like it has finally finalised a settlement that should allow it to put litigation over its role in fuelling the US opioid ep

UK must not overlook manufacturing in life sciences drive

Astellas hit by US patent verdict for incontinence drug

Illumina CEO resigns amid investor pressure

CMS extends list of drugs with penalties for price hikes

FDA panel gives unanimous support to Leqembi

Teva gets its US opioid settlement over the finish line

Sanofi drops two more programmes in R&D clear-out

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks